Navigation Links
Diabetes drug could treat leading cause of blindness
Date:5/7/2012

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

In laboratory rat and cell-culture experiments, the scientists found that metformin, which is commonly used to control blood sugar levels in type 2 diabetes, also substantially reduced the effects of uveitis, an inflammation of the tissues just below the outer surface of the eyeball. Uveitis causes 10 to 15 percent of all cases of blindness in the United States, and is responsible for an even higher proportion of blindness globally. The only treatment now available for the disorder is steroid therapy, which has serious side effects and cannot be used long-term.

"Uveitis has various causes the most common are infectious diseases and autoimmune disorders but they all produce inflammation within the eye," said UTMB professor Kota V. Ramana, senior author of a paper on the study now online in the journal Investigative Ophthalmology & Visual Science. "Metformin inhibits the process that causes that inflammation."

The scientists discovered metformin's efficacy when they tested it in rats given an endotoxin that mimicked the inflammatory effects of bacterial infection. The results showed clearly that metformin was a very effective anti-uveitis agent.

"We found that the drug is therapeutic as well as preventive if we gave our rats the drug beforehand, they didn't develop uveitis, and if we gave it after uveitis had developed, it was therapeutic," said UTMB professor Satish Srivastava, also an author of the IOVS paper. "Metformin's strong anti-inflammatory properties make this possible."

According to the researchers, metformin works by activating an enzyme called AMPK, which in turn damps down the activity of the protein NF-kappa B. The inhibition of NF-kappa B suppresses the production of inflammatory signaling molecules cytokines and chemokines needed to initiate and sustain uveitis.

Because metformin is already used so widely as a therapy for diabetes, the UTMB scientists believe that it has a good chance of being rapidly adopted as an anti-uveitis drug.

"I think after a few more pre-clinical studies are done, we can get this drug to patients in a shorter time than usual," Ramana said. "Its safety is already known, so all that we need to see is its efficacy in humans."


'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Study identifies possible protective blood factors against Type 2 diabetes
2. New research finds no association between white potato consumption (baked, boiled mashed) and obesity, Type 2 diabetes or systemic inflammation
3. Xenotransplantation as a therapy for type 1 diabetes
4. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
5. Diabetes Groups Issue New Guidelines on Blood Sugar
6. Cellular pathway linked to diabetes, heart disease
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
9. Common Plastics Chemical Might Boost Diabetes Risk
10. Mouse Study Hints at New Path for Diabetes Treatment
11. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... World Patent Marketing , a vertically ... automotive invention that improves the storage features of a pick up truck. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Over the next five ...
(Date:4/29/2016)... Arizona (PRWEB) , ... April 29, 2016 , ... ... Healing and Spiritual Awakening , announces the addition Onnit brand Alpha BRAIN and ... The addition of Onnit brain and mood optimization products to the store is ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... Philadelphia, PA (PRWEB) , ... April 29, 2016 ... ... Pennsylvania announced that student team BioCellection won the $30,000 Perlman Grand Prize of ... Impact Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
(Date:4/27/2016)... 2016 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer, will present at the Deutsche Bank 41st ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 ... on the Presentations and Webcasts section of Shire,s Investor website ... will be available on this same website for approximately 90 ...
Breaking Medicine Technology: